City Therapeutics, Inc. CTY
20.11 USD +0.48 (+2.47%)
Nov 11, 2026, 10:00 AM EST
19.65 Day range 21.31
15.81 52-week range 23.88
- YTD
- -10.25%
- 1 year
- -10.25%
News
benzinga.com Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32 Jefferies analyst Maury Raycroft initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $32.
benzinga.com This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated coverage on Mentari, MongoDB, Comfort Systems and Ross Stores; City Therapeutics received an early-stage biotech rating.
benzinga.com Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46 Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.
benzinga.com City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1 City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, today announced that the first participant has…
benzinga.com Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.
globenewswire.com City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease City's second program to advance into the…
benzinga.com Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34 Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.
globenewswire.com Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi)…